Co-Authors
This is a "connection" page, showing publications co-authored by HAGOP M KANTARJIAN and ELIZABETH SHPALL.
Connection Strength
2.128
-
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood Cancer J. 2024 08 07; 14(1):129.
Score: 0.245
-
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023 11; 98(11):1711-1720.
Score: 0.229
-
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol. 2022 01 29; 15(1):12.
Score: 0.205
-
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540.
Score: 0.158
-
A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission. Transplant Cell Ther. 2024 Sep 26.
Score: 0.062
-
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer. 2024 Oct 01; 130(19):3333-3343.
Score: 0.060
-
Clonal evolution of hematopoietic stem cells after cancer chemotherapy. bioRxiv. 2024 May 24.
Score: 0.060
-
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol. 2024 05; 99(5):836-843.
Score: 0.059
-
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica. 2023 09 01; 108(9):2331-2342.
Score: 0.057
-
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv. 2023 07 25; 7(14):3573-3581.
Score: 0.057
-
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol. 2023 09; 98(9):1383-1393.
Score: 0.057
-
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease?(MRD) recurrence following MRD-negative remission. Am J Hematol. 2022 11; 97(11):E408-E411.
Score: 0.054
-
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022 May; 9(5):e350-e360.
Score: 0.052
-
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 2022 03 24; 139(12):1908-1919.
Score: 0.052
-
Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 Jan; 36(1):298.
Score: 0.051
-
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer. 2021 10 01; 127(19):3541-3551.
Score: 0.049
-
Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 01; 36(1):257-262.
Score: 0.049
-
Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 07; 56(7):1746-1749.
Score: 0.048
-
Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020 10 08; 136(15):1786-1789.
Score: 0.047
-
Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood. 2020 03 12; 135(11):862-865.
Score: 0.045
-
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020 05 15; 126(10):2193-2205.
Score: 0.045
-
KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Blood. 2016 12 15; 128(24):2819-2823.
Score: 0.036
-
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016 09 01; 126(9):3363-76.
Score: 0.035
-
Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biol Blood Marrow Transplant. 2016 07; 22(7):1218-1226.
Score: 0.034
-
Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for?Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):47-53.
Score: 0.033
-
The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):319-26.
Score: 0.029
-
Regulation of HIF-1a signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther. 2012 Aug; 13(10):858-70.
Score: 0.027
-
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012 Apr; 18(4):584-92.
Score: 0.025
-
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One. 2011; 6(8):e23108.
Score: 0.025
-
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma. 2010 Aug; 51(8):1478-84.
Score: 0.023
-
Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia. 2010 Mar; 24(3):666-8.
Score: 0.022
-
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009 May 01; 115(9):1899-905.
Score: 0.021
-
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S261-5.
Score: 0.021
-
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer. 2007 Jul 15; 110(2):340-4.
Score: 0.019
-
High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Feb; 39(3):157-64.
Score: 0.018
-
Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer. 2006 Jun 15; 106(12):2664-71.
Score: 0.017